Physician profile
William K Drell
NPI 1932184983
$2,108.14
in general payments reported to CMS, 2019-2025
14 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $246 · 2021: $156 · 2022: $415 · 2023: $375 · 2024: $119 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.30 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $321.41 | 2019-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $241.12 | 2019-2020 | |
| Alkermes, INC. | $208.36 | 2021-2022 | |
| Tris Pharma INC | $124.98 | 2022 | |
| Allergan, INC. | $124.64 | 2020 | |
| Janssen Pharmaceuticals, INC | $123.31 | 2019 | |
| Sunovion Pharmaceuticals INC. | $121.23 | 2019 | |
| Neurocrine Biosciences, INC. | $119.21 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $115.11 | 2025 | Auvelity |
| Brainsway USA INC | $57.28 | 2022 | |
| Supernus Pharmaceuticals, INC. | $31.07 | 2021-2022 | |
| Abbvie INC. | $19.50 | 2022 | |
| Bausch Health US, LLC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Drell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.